

COMMENT OPEN



Cochrane corner: topical anaesthetics for pain control following corneal abrasions

Annali L. Lawrenson¹ and John G. Lawrenson²✉

© The Author(s) 2023

Eye (2024) 38:646–647; <https://doi.org/10.1038/s41433-023-02762-y>

Traumatic corneal abrasions, causing a disruption of superficial corneal epithelial integrity, are a common presentation in both general and ophthalmic emergency departments [1–4]. Corneal epithelial defects can also occur following commonly performed ophthalmic surgical procedures, such as photorefractive keratectomy (PRK), alcohol delamination and corneal cross-linking. The high density of nociceptors in the cornea means that corneal abrasions are associated with significant pain, which is most intense at initial presentation and during the subsequent 24 to 48 h. The current NICE Clinical Knowledge Summary on corneal superficial injury [5], providing an evidence-based clinical guideline for UK primary care professionals, recommends simple oral analgesia such as paracetamol, with the addition of lubricating eye drops or ointment for additional pain relief. Whilst established dogma within ophthalmology advocates that topical anaesthetics should not be prescribed for corneal-abrasion-related pain due to safety concerns and the potential for abuse [6], this view has recently been challenged by emergency physicians [7, 8]. By contrast, surveys of eyecare professionals conducted in the USA reported almost universal opposition to this practice [9, 10]. The publication of the Cochrane Review by Sulewski et al. on ‘Topical ophthalmic anaesthetics for corneal abrasions’ is, therefore, very timely [11].

The review, which included nine randomised controlled trials (RCTs) recruiting 556 adult participants investigated the effectiveness and safety of self-administered topical anaesthetics for the relief of pain compared to a non-anaesthetic control group (placebo or other treatment). Four RCTs (314 participants) analysed individuals with traumatic abrasions presenting in an emergency department setting and five trials (242 participants) investigated post-surgical epithelial defects. Participants were supplied with one of the commonly used topical ophthalmic anaesthetics, specifically, tetracaine (used in 5 RCTs), proparacaine (3 trials) or lidocaine (1 RCT). Adjunctive oral analgesia was also used in all but one study, either using a designated dosing regime or ‘as required’. Pain intensity was evaluated using visual analogue scales (VAS) or numerical scales, where higher scores represented higher pain intensities. The effect of treatment on epithelial healing rates was also evaluated by slit-lamp biomicroscopy and the proportion of participants with adverse events was reported at the longest follow up time.

Topical anaesthetics had little or no effect in reducing self-reported pain for traumatic or surgically created abrasions from

baseline to 24 h compared to an inactive control. However, based on low certainty evidence from one trial of participants with traumatic abrasions, anaesthetics may lower pain scores at 24–48 h. Only one post-surgical RCT reported on pain control up to 72 h and found that the intervention had little or no effect on post-surgical pain. Overall, for the trials included in the quantitative analysis, there was no significant reduction in resolution of epithelial defects between anaesthetic and control groups, nor in the proportion of eyes with complications, although the certainty of the evidence is very low for all safety outcomes mostly because of risk of bias and small sample sizes.

In recent years, Cochrane Eyes and Vision have produced a suite of reviews that have examined the management of corneal abrasions [12–14]. The findings of this latest review are unlikely to change practice and convince the eye care community of the safety of supplying topical anaesthetics for pain relief, even if provided in limited dose-vials and used for short periods. The review authors acknowledge that they had very low confidence in the efficacy data. Furthermore, the effect sizes for pain reduction were generally small and typically less than two units lower with anaesthetic on a 10-point VAS pain scale. Studies in emergency settings have attempted to define the minimum clinically important difference (MCID) for acute pain severity by measuring the change in VAS score associated with adequate pain control. A mean reduction in VAS of at least 30% was found to represent a clinically important difference in pain severity that corresponded to patients’ perception of adequate pain control. [15]

Although there were no safety concerns arising from the included trials, the review authors do not discount the potential for ocular morbidity, particularly in a ‘real world’ setting where patients are not as closely monitored as in the experimental studies. The growing opioid crisis in the USA has created an impetus for opioid-sparing pain management and this may explain the desire to seek alternative methods to control pain arising from corneal-abrasion associated pain in the emergency department. However, further research is still needed, with larger, better-quality trials and longer follow up times to provide the evidence base needed to justify a change in practice.

REFERENCES

1. Vernon SA. Analysis of all new cases seen in a busy regional centre ophthalmic casualty department during 24-week period. *J R Soc Med.* 1983;76:279–82.

¹Emergency Department, Epsom & St Helier University Hospitals NHS Trust, KT18 7EG Epsom, UK. ²School of Health and Psychological Sciences, City, University of London, EC1V 0HB London, UK. ✉email: j.g.lawrenson@city.ac.uk

Received: 7 September 2023 Revised: 12 September 2023 Accepted: 15 September 2023

Published online: 25 September 2023

2. Edwards RS. Ophthalmic emergencies in a district general hospital casualty department. *Br J Ophthalmol*. 1987;71:938–42.
3. Bhopal RS, Parkin DW, Gillie RF, Han KH. Pattern of ophthalmological accidents and emergencies presenting to hospitals. *J Epidemiol Community Health*. 1993;47:382–7.
4. Vartsakis G, Fahy G. The profile of patients attending a triaged eye emergency service. *Ir J Med Sci*. 2014;183:625–8.
5. NICE. Corneal superficial injury. *Clinical Knowledge Summaries* 2022. [Available from: <https://cks.nice.org.uk/topics/corneal-superficial-injury/>]. Accessed 31 Aug 2023.
6. Patel M, Fraunfelder FW. Toxicity of topical ophthalmic anesthetics. *Expert Opin Drug Metab Toxicol*. 2013;9:983–8.
7. Waldman N, Winrow B, Densie I, Gray A, McMaster S, Giddings G, et al. An observational study to determine whether routinely sending patients home with a 24-h supply of topical tetracaine from the emergency department for simple corneal abrasion pain is potentially safe. *Ann Emerg Med*. 2018;71:767–78.
8. Shipman S, Painter K, Keuchel M, Bogie C. Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. *Ann Emerg Med*. 2021;77:338–44.
9. Anderson-Quinones C, Zhu R, Tolley EA, Vestal R, Asbell P. Topical anesthetics for analgesia in acute corneal abrasion: eye care providers survey. *Eye Contact Lens*. 2023;49:143–6.
10. Lee MD, Driver TH, Seitzman GD. Cornea specialists do not recommend routine usage of topical anesthetics for corneal abrasions. *Ann Emerg Med*. 2019;74:463–6.
11. Sulewski M, Leslie L, Liu SH, Ifantides C, Cho K, Kuo IC. Topical ophthalmic anesthetics for corneal abrasions. *Cochrane Database Syst Rev*. 2023;8:CD015091.
12. Lim CH, Turner A, Lim BX. Patching for corneal abrasion. *Cochrane Database Syst Rev*. 2016;7:CD004764.
13. Wakai A, Lawrenson JG, Lawrenson AL, Wang Y, Brown MD, Quirke M, et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. *Cochrane Database Syst Rev*. 2017;5:CD009781.
14. Algarni AM, Guyatt GH, Turner A, Alamri S. Antibiotic prophylaxis for corneal abrasion. *Cochrane Database Syst Rev*. 2022;5:CD014617.
15. Lee JS, Hobden E, Stiell IG, Wells GA. Clinically important change in the visual analog scale after adequate pain control. *Acad Emerg Med*. 2003;10:1128–30.

AUTHOR CONTRIBUTIONS

All authors contributed to the article concept, manuscript preparation, and revision.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to John G. Lawrenson.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023